Pharmaceutical company Merck is definitely expanding its biologics protfolio. The firm just acquired two biotech companies: GlycoFi, Inc. and Abmaxis, Inc.

lebanon-based GlycoFi boasts of a proprietal yeast glycoengineering technology that has potential use in developing novel biotherapeutics. Abmaxis, on the other hand, is a private biopharmaceutical company which optimizes and humanizes antibodies for human therapeutics and diagnostics.

The acquisitions costed Merck a sum of $400 million, with GlycoFi taking the lion's share at $400 million. More of the Merck acquisitions from BusinessWeek Online and The PharmVoice.